News
-
In its third quarter results for 2011, Novartis announced that, “In the US, NVA237 will require additional clinical data to support submission and thus will be delayed.” Furthermore, the company warned, “The changes to the… Read more . . .
-
Ken Cunningham, who recently joined the board of UK pharmaceutical and particle engineering company Prosonix, will lead the company’s new scientific advisory board. Joining Cunningham on Prosonix’s SAB are: Peter Barnes, Professor of Thoracic Medicine… Read more . . .
-
Massachusetts respiratory pharmaceutical company Acton Pharmaceuticals has entered into a licensing agreement with Sanofi US that gives Acton exclusive US rights to develop and market prescription Nasacort HFA triamcinolone acetonide nasal aerosol for the treatment… Read more . . .
-
Merck has announced results of two Phase 3 clinical studies of Dulera mometasone furoate/formoterol fumarate inhalation aerosol for the treatment of COPD that show statistically significant improvement in lung function in most of the combinations… Read more . . .
-
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) Pharmaxis has adopted a positive opinion recommending the approval of a marketing authorization for Bronchitol inhaled dry powder mannitol formulation “for the treatment… Read more . . .
-
Over the past few months, the US Health and Human Service Department’s Agency for Healthcare Research and Quality (AHRQ) has issued several statistical briefs and a research finding regarding rising expenditures for asthma medications used… Read more . . .
-
Impel NeuroPharma has announced new funding for development of its Pressurized Olfactory Delivery (POD) device from a variety of sources. The company says that in addition to closing on over a half million dollars of… Read more . . .
-
Two experts in particle manufacturing for inhaled dry powder formulations, Hovione and Bend research, have entered into a non-exclusive collaboration in which they will have access to each other’s technologies. The partnership also gives Bend… Read more . . .
-
Insight Pharmaceuticals has voluntarily recalled a single lot of its Nostrilla oxymetazoline hydrochloride nasal spray due to possible contamination with Burkholderia cepacia bacteria. Nostrilla is available without prescription, and lot #11G075, which consisted of 34,092… Read more . . .
-
Hovione has launched a new service to provide proof of concept formulation for new dry powder formulations within a few weeks. The company says that its Rapid Proof of Concept Study will further simplify DPI… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here

